Shared Antigenic Epitopes and Pathobiological Functions of Anti-p185 Monoclonal Antibodies
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
We have studied two anti-p185 antibodies: the monoclonal antibody 7. 16.4 and rhuMAb 4D5, which were raised against the the ectodomain of rat (p185(neu)), and the human (p185(her2/neu)) homolog, respectively. Studies on the structure of these two antibodies indicate that they share structural similarity in the variable region, especially the CDR3 region, which determines the antibody-antigen interaction. Further studies by flow cytometry revealed that 7.16.4 can compete with rhuMAb4D5 for binding to the cell surface p185(her2/neu), suggesting that these two antibodies share an epitope on the p185 receptor. Furthermore, 7.16.4 can also inhibit proliferation and transformation caused by p185(her2/neu). Moreover the rhuMAb 4D5 binds to the rat p185(neu). With the observation that 7.16.4 positively stains human breast cancer tissues that overexpress p185(her2/neu), 7.16.4 may be useful for the pathological diagnosis and therapy of human tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Canonical structures for the hypervariable regions of immunoglobulins
Chothia, C., & Lesk, A. M. (1987) · Journal of Molecular Biology · doi:10.1016/0022-2836(87)90412-8 · Cited by 1,406
Cited by
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
Park, S., Jiang, Z., Mortenson, E. D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N. K., Greene, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.014 · Cited by 577
“Anti-neu antibody (7.16.4) recognizes the juxtamembranal region of rat neu and competes with 4D5, the precursor of trastuzumab, for binding and inhibition of tumor growth (Zhang et al., 1999).”
BackgroundMethodInfluentialSelf-citationErbB receptors: from oncogenes to targeted cancer therapies
Zhang, H., Berezov, A., Wang, Q., Zhang, G., Drebin, J., Murali, R., & Greene, M. I. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32278 · Cited by 574
Self-citationOng, L.-T., Lee, W. C., Ma, S., Oguz, G., Niu, Z., Bao, Y., Yusuf, M., Lee, P. L., Goh, J. Y., Wang, P., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2201376119 · Cited by 572
Stagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016569108 · Cited by 496
Calvo, M., Zhu, N., Tsantoulas, C., Ma, Z., Grist, J., Loeb, J. A., & Bennett, D. L. H. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5169-09.2010 · Cited by 167
“…an irreversible specific erbB inhibitor, PD168393 (Bose et al., 2006), which blocks the ATP binding site of the receptor, or mAb 7.16.4, which specifically binds to the extracellular domain of erbB2 (sharing antigenic epitopes with Herceptin, Genentech) (Katsumata et al., 1995; Zhang et al., 1999).”
BackgroundInfluentialEffective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells
Mortenson, E. D., Park, S., Jiang, Z., Wang, S., & Fu, Y.-X. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2522 · Cited by 66
Metadata
- Authors
- Zhang, H., Wang, Q., Montone, K. T., Peavey, J. E., Drebin, J. A., Greene, M. I., & Murali, R.
- Venue
- Experimental and Molecular Pathology
- Publisher
- Elsevier BV
- Published
- 1999-09
- Volume
- 67
- Issue
- 1
- Pages
- 15-25
- ISSN
- 0014-4800 (ISSN-L)
- OpenAlex
- W2042190557
- Cited by
- 44
- References
- 1
- FWCI
- 0.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.